Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label active-controlled study of HS-10390 tablets in primary IgA nephropathy
CTR20243735Phase 2Active
- Sponsor
- Changzhou Hengbang Pharmaceutical
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HS-10390 in IgA nephropathy (IgAN), sponsored by Changzhou Hengbang Pharmaceutical. Started Dec 2024; status: active.
02
Drugs
HS-10390
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on CTR20243735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243735.